• Greater Twin Cities: 715.294.4371

  • Search

Purchase Nilotinib (Tasigna) capsules online


Nilotinib (trade names include Tasigna, Tasinga, Nilotib) is an anti cancer medication from protein kinase inhibitors pharmacological group. This medicine is used for the treatment of Philadelphia chromosome (Ph+)-positive chronic myelogenous leukaemia. It is also in research phases for the therapy of Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis, dementia, Huntington's disease, gastrointestinal stromal tumor. It works by inhibiting various enzymes called kinases.

How and where to order Nilotinib (Tasigna) 200 mg capsules online:

Shop: BUY NILOTINIB ONLINE
Prices: from $22.07 per pill
Discount: 5% coupon: 5OFF
Forms: Nilotinib (Tasigna) 200 mg capsules
Quantity: 28, 56 pills
Type: Tasigna (Nilotinib) generic
Payment: Visa, MasterCard, AmEx, Bitcoin
Delivery: Unregistered mail or trackable courier
Shipping: Worldwide, including USA, UK, Europe, Canada, Australia

Related medications:

  • Abemaciclib (Verzenio, Verzenios)
  • Abiraterone (Zytiga)
  • Anastrozole (Arimidex)
  • Axitinib (Inlyta)
  • Bosutinib (Bosulif)
  • Brigatinib (Alunbrig)
  • Encorafenib (Braftovi)
  • Gefitinib (Iressa)
  • Ibrutinib (Imbruvica)
  • Imatinib (Gleevec)
  • Larotrectinib (Vitrakvi)
  • Letrozole (Femara)
  • Melphalan (Alkeran)
  • Nintedanib (Ofev, Vargatef)
  • Olmutinib (Olita)
  • Pazopanib (Votrient)
  • Ponatinib (Iclusig)
  • Regorafenib (Stivarga)
  • Ribociclib (Kisqali)
  • Rociletinib (Xegafri)
  • Sorafenib (Nexavar)
  • Tivozanib (Fotivda)


    Pharmacological and medical categories:

  • Anti cancer drugs
  • Antineoplastic medicines
  • Oncological treatment
  • Leukaemia therapy


    ATC codes:

  • L - Antineoplastic and immunomodulating agents
  • L01 - Antineoplastic agents
  • L01X - Other antineoplastic agents
  • L01XE - Protein kinase inhibitors
  • L01XE08 - Nilotinib


    ICD-10 codes:

  • Malignant neoplasm of other connective and soft tissue - C49
  • Gastrointestinal stromal tumor, unspecified site - C49.A0
  • Myeloid leukemia - C92
  • Mental disorders due to known physiological conditions - F01-F09
  • Huntington's disease - G10
  • Spinal muscular atrophy and related syndromes - G12
  • Amyotrophic lateral sclerosis - G12.21
  • Parkinson's disease - G20
  • Alzheimer's disease - G30


    Pregnancy categories:

  • D - Australia
  • D - United States (Positive evidence of risk)


    Salts and other forms:

  • Nilotinib Base
  • Nilotinib Hydrochloride
  • Nilotinib Hydrochloride Dihydrate
  • Nilotinib Hydrochloride Monohydrate


    Synonyms, international and chemical names:

  • AMN107
  • Nilotinib HCl
  • Nilotinibe
  • Nilotinibi
  • Nilotinibum
  • Nilotynib


    Brands, generics, trade names:

  • Tasigna - Novartis
  • Tasinga - Novartis
  • Nilotib - Caprane Pharmaceutical
  • Nilotinib - Actiza Pharmaceutical


    Indications and usage:

    Tasigna (Nilotinib) is a kinase inhibitor indicated forthe treatment of:

  • Adult and pediatric patientsgreater than or equal to 1 year of agewith newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase.
  • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib.
  • Pediatric patients greater than or equal to 1 year of agewith Ph+ CML-CP resistant or intolerant to prior tyrosine-kinase inhibitor (TKI) therapy.


    Dosage and administration:

  • Recommended Adult Dose: Newly diagnosed Ph+ CML-CP: 300 mg orally twice daily. Resistant or intolerant Ph+ CML-CP and CML-AP: 400 mg orallytwice daily.
  • Recommended Pediatric Dose: Newly Diagnosed Ph+ CML-CP or Ph+ CML-CP resistant or intolerant to prior TKI therapy: 230 mg/m2orally twice daily, rounded to the nearest 50 mg dose (to a maximum single dose of 400 mg).
  • See Dosage and Administration for full dosing instructions and dose-reduction instructions for toxicity.
  • Reduce starting dose in patients with baseline hepatic impairment.
  • Eligible newly diagnosed adult patients with Ph+ CML-CP who have received Tasigna for a minimum of 3 years and have achieved a sustained molecular response (MR4.5) and patients with Ph+ CML-CP resistant or intolerant to imatinib who have received Tasigna for at least 3 years and have achieved a sustained molecular response (MR4.5) may be considered for treatment discontinuation.


    Dosage forms and strengths:

    Tasigna (Nilotinib) capsules: 50 mg, 150 mg, and 200 mg


    Contraindications:

    Nilotinib is contraindicated in patients with hypokalemia, hypomagnesemia, or long QT syndrome.


    Warnings and precautions:

  • Myelosuppression: Monitor complete blood count (CBC) during therapy and manage by treatment interruption or dose-reduction.
  • Cardiac and Arterial Vascular Occlusive Events: Evaluate cardiovascular status, monitor and manage cardiovascular risk factors during Tasigna therapy.
  • Pancreatitis and Elevated Serum Lipase: Monitor serum lipase; if elevations are accompanied by abdominal symptoms, interrupt doses and consider appropriate diagnostics to exclude pancreatitis.
  • Hepatotoxicity: Monitor hepatic function tests monthly or as clinically indicated.
  • Electrolyte Abnormalities: Tasigna can cause hypophosphatemia, hypokalemia, hyperkalemia, hypocalcemia, and hyponatremia. Correct electrolyte abnormalities prior to initiating Nilotinib and monitor periodically during therapy.
  • Tumor Lysis Syndrome: Maintain adequate hydration and correct uric acid levels prior to initiating therapy with Tasigna.
  • Hemorrhage: Hemorrhage from any site may occur. Advise patients to report signs and symptoms of bleeding and medically manage as needed.
  • Fluid Retention: Monitor patients for unexpected rapid weight gain, swelling, and shortness of breath. Manage medically.
  • Effects on Growth and Development in Pediatric Patients: Growth retardation hasbeen reported in pediatric patients treated with Tasigna. Monitor growth and development in pediatric patients.
  • Embryo-Fetal Toxicity: Advise patients of potential risk to a fetus and to use effective contraception.
  • Treatment Discontinuation: Patients must have typical BCR-ABL transcripts. An FDA-authorized test with a detection limit below MR4.5 must be used to determine eligibility for discontinuation. Patients must be frequently monitored by the FDA authorized testto detect possible loss of remission.


    Adverse reactions, side effects:

    The most commonly reported non-hematologic adverse reactions ( >= 20%) in adult and pediatric patients were nausea, rash, headache, fatigue, pruritus, vomiting, diarrhea, cough, constipation, arthralgia, nasopharyngitis, pyrexia, and night sweats. Hematologic adverse drug reactions include myelosuppression: thrombocytopenia, neutropenia, and anemia.


    Drug interactions:

  • Strong CYP3A Inhibitors: Avoid concomitant use with Tasigna, or reduce Tasigna dose if co-administration cannot be avoided.
  • Strong CYP3A Inducers: Avoid concomitant use with Tasigna.
  • Proton Pump Inhibitors: Use short-acting antacids or H2 blockers as an alternative to proton pump inhibitors


    References:

  • Nilotinib main article on Wikipedia: https://en.wikipedia.org/wiki/Nilotinib
  • Nilotinib compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib
  • Nilotinib Hydrochloride compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib-hydrochloride
  • Nilotinib Hydrochloride Monohydrate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/16757572
  • Nilotinib Hydrochloride Dihydrate compound on PubChem: https://pubchem.ncbi.nlm.nih.gov/compound/Nilotinib-hydrochloride-dihydrate
  • Nilotinib on DrugBank: https://www.drugbank.ca/drugs/DB04868
  • Nilotinib Hydrochloride Monohydrate on DrugBank: https://www.drugbank.ca/salts/DBSALT001325
  • Nilotinib FAQ on MedlinePlus: https://medlineplus.gov/druginfo/meds/a608002.html
  • Tasigna (Nilotinib) capsules drug label info on DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup...
  • Nilotinib international drug names on Drugs.com: https://www.drugs.com/international/nilotinib.html
  • Nilotinib for sale on Pharma Doctor: https://pharma-doctor.com/nilotinib.html
  • Tasigna (Nilotinib) 150 mg, 200 mg capsules official website: https://www.us.tasigna.com/
  • Tasigna (Nilotinib) capsules official prescribing information and medication guide from the U.S. FDA: https://www.accessdata.fda.gov/drugsatfda_docs/label...
  • Tasigna (Nilotinib) capsules product monograph on Novartis pharmaceutical company website: https://www.novartis.us/sites/www.novartis.us/files/tasigna...
  • Tasigna (Nilotinib) 150 mg hard capsules patient information leaflet on Medicines.org.uk: https://www.medicines.org.uk/emc/files/pil.5852.pdf
  • Tasigna (Nilotinib) 200 mg hard capsules patient information leaflet on Medicines.org.uk: https://www.medicines.org.uk/emc/files/pil.6251.pdf

    Updated: March 2020
    Reviewed: March 2020
  • Preclinical Testing Solutions
    Throughout the
    Product Innovation Cycle.